NTT-DOCOMO/NEC
26.2.2024 09:06:25 CET | Business Wire | Press release
NTT DOCOMO, INC. and NEC Corporation announced today that they plan to establish a joint venture company, OREX SAI, INC. on April 1 to provide OREX Packages solutions for the full-scale global deployment of Open RAN services.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240226531069/en/
Overview of OREX SAI (Graphic: Business Wire)
OREX SAI will locally source products and services from members of OREX PARTNERS in each market and perform system verifications to deliver mobile networks tailored to the needs of each overseas telecommunications operator. Leveraging NEC’s established business infrastructure and global network in over 50 countries and territories, the joint venture will accelerate its global expansion of Open RAN business.
In addition, DOCOMO and NEC plan to strengthen cooperation with OREX PARTNERS through OREX SAI to promote the commercialization and realization of true Open RAN that enables the interoperability of equipment and systems from diverse vendors.
The joint venture will procure all necessary Open RAN network equipment and software from OREX PARTNERS, and then conduct system verification for the planning and construction of optimal mobile networks tailored to each telecom operator. Full-stack services will include planning, construction, maintenance and operation under the OREX Packages framework.
DOCOMO established the O-RAN ALLIANCE with leading global telecom operators in February 2018 and launched the world’s first nationwide Open RAN 5G service in Japan in March 2020. Since introducing the OREX® brand in February 2023, DOCOMO has been supporting Open RAN verifications for global telecom operators to help realize more open mobile networks around the world.
NEC, having delivered Open RAN solutions to telecom operators in Japan and other countries, was selected by DOCOMO as a vendor for virtualized radio access networks (vRANs), one of DOCOMO’s 5G commercial services in Japan. With extensive experience in building communication infrastructure around the world, NEC offers strong system-integration (SI) capabilities.
In their collaboration with OREX PARTNERS to realize Open RAN, DOCOMO and NEC recognize the importance of optimizing local product and service delivery. In response, they will now form a joint venture company to establish a global system capable of accelerating the realization of Open RAN.
Hiroshi Kobayashi, President and CEO of OREX SAI, said, “We are excited to bring our true Open RAN solutions to telecom operators worldwide through the joint venture OREX SAI, which combines DOCOMO’s Open RAN implementation expertise, OREX’s innovative solutions and NEC’s global system-integration capabilities. We are committed to driving innovation and connectivity for all, making global telecommunications open, seamless and inclusive.”
Going forward, OREX SAI will work with OREX PARTNERS to provide optimal products and services that accelerate the global adoption of high-quality, cost-effective and energy-efficient Open RAN solutions. In addition, they will enhance cooperation with global partners to foster a vibrant and open ecosystem.
The new company will also explore application of the NTT’s IOWN all-photonic network for transmission, the use of low-power servers equipped with optoelectronic devices, and collaboration with the Cognitive Foundation®.
Joint Venture Overview |
|
Official Name |
OREX SAI, INC. |
Headquarters |
59-16 Nisshin-cho, Kawasaki-ku, Kawasaki City, Kanagawa, Japan 210-0024 |
President and CEO |
Hiroshi Kobayashi |
Business |
|
Total Assets |
JPY 16 billion (including capital reserve) |
Establishment |
April 1, 2024 (tentative) |
Shareholders |
DOCOMO 66% and NEC 34% |
OREX is a trademark of NTT DOCOMO, INC.
For more detailed information, please refer to the full press release available at www.docomo.ne.jp/english/info/media_center/pr/
About NTT DOCOMO
NTT DOCOMO, Japan’s leading mobile operator with over 89 million subscriptions, is one of the world’s foremost contributors to 3G, 4G and 5G mobile network technologies. Beyond core communications services, DOCOMO is challenging new frontiers in collaboration with a growing number of entities ("+d" partners), creating exciting and convenient value-added services that change the way people live and work. Under a medium-term plan toward 2020 and beyond, DOCOMO is pioneering a leading-edge 5G network to facilitate innovative services that will amaze and inspire customers beyond their expectations.
https://www.docomo.ne.jp/english/
About NEC Corporation
NEC Corporation has established itself as a leader in the integration of IT and network technologies while promoting the brand statement of “Orchestrating a brighter world.” NEC enables businesses and communities to adapt to rapid changes taking place in both society and the market as it provides for the social values of safety, security, fairness and efficiency to promote a more sustainable world where everyone has the chance to reach their full potential. For more information, visit NEC at https://www.nec.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240226531069/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom